Peter M. Fleischut, MD Group Senior Vice President & Chief Information and Transformation Officer | New York Presbyterian Hospital
Peter M. Fleischut, MD Group Senior Vice President & Chief Information and Transformation Officer | New York Presbyterian Hospital
The Transcatheter Cardiovascular Therapeutics (TCT) conference, a prominent event in interventional cardiovascular medicine, took place this year in Washington, DC. Founded nearly four decades ago by Martin Leon, MD, the conference is organized by the Cardiovascular Research Foundation and gathers experts worldwide to discuss developments in the field.
This year's TCT 2024 saw over 10,000 attendees focusing on a new theme: "from intervention to prevention." NewYork-Presbyterian doctors from Columbia and Weill Cornell Medicine played significant roles as speakers and program directors. Notable participants included Dr. Leon; Ajay Kirtane, MD; and Sahil Parikh, MD.
NewYork-Presbyterian clinicians also contributed to the program development committee. Among them were Russell A. Brandwein, MS, PA-C; Brian G. DeRubertis, MD; Mahesh V. Madhavan, MD; Margaret B. McEntegart, MD; Tamim M. Nazif, MD; Vivian G. Ng, MD; Megha Prasad, MD; Sanjum S. Sethi, MD; and Torsten P. Vahl, MD.
Various NewYork-Presbyterian cardiologists presented research on early intervention and treatment options for coronary artery disease and structural heart disease. Three live cases were highlighted: a redo transcatheter aortic valve replacement (TAVR), a challenging TAVR case, and a case from the EMPOWER CAD trial using intravascular lithotripsy.
Jeffrey W. Moses, MD received the TCT 2024 Master Operator Award for his contributions to interventional cardiology.
Significant presentations included findings from the EARLY TAVR trial published in the New England Journal of Medicine that suggested benefits of earlier intervention for severe asymptomatic aortic stenosis (AS). Allan Schwartz, MD was co-principal investigator with Dr. Leon serving as study chairman.
Dr. Kirtane presented results from the ECLIPSE trial comparing strategies for treating severe coronary calcification during percutaneous coronary intervention (PCI). The trial found similar outcomes between conventional balloon angioplasty and orbital atherectomy when guided by intravascular imaging.
The TRISCEND II trial showed promising results for treating severe tricuspid regurgitation with a minimally invasive valve replacement system called EVOQUE. Principal investigator Dr. Kodali noted its potential to broaden treatment options for patients unable to undergo surgery.
A live case concluded the all-women EMPOWER CAD trial led by Drs. McEntegart and Prasad using intravascular lithotripsy on calcified arteries in women—a traditionally understudied group in cardiology.
Additional trials discussed at TCT 2024 included ALIGN-AR Trial led by Dr. Vahl assessing JenaValve Pericardial TAVR System's efficacy for severe aortic regurgitation management without surgery; ACURATE IDE Trial overseen by Dr. Nazif evaluating ACURATE Valve device safety for TAVR in severe AS patients; and TAVR UNLOAD Trial led by Dr. Kodali exploring TAVR's effect on heart strain reduction in moderate AS patients with heart failure.
###
Alerts Sign-up